Healthcare Industry News: mitral valve
News Release - April 8, 2014
CardiAQ(TM) Valve Technologies Inc. (CardiAQ) appoints Paul Cornelison as Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs“Paul brings a wealth of mitral space experience, and I am personally delighted that he has chosen to join CardiAQ to help solidify our position as the undisputed leader in percutaneous mitral valve replacement as an alternative to open heart surgery.” - Rob Michiels, CEO, CardiAQ
IRVINE, Calif.--(Healthcare Sales & Marketing Network)--CardiAQ Valve Technologies Inc., which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter mitral valve Implantation (TMVI), today announced that it has appointed Paul Cornelison as Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs.
Most recently, Paul was Vice President of Regulatory Affairs & Quality Assurance at Cardiac Dimensions, Inc., one of the earliest percutaneous mitral valve repair companies. Previously, he held regulatory and quality assurance positions at Arrow International (now part of Teleflex Medical); RCRI Inc.; St. Jude Medical (Daig Division); Angeion Corporation; Telectronics Pacing Systems; Aequitron Medical; and, Lake Region Manufacturing. He holds a Master’s degree in Engineering (Management of Technology) from the University of Pennsylvania; and Bachelor of Arts degrees in Management and Spanish from St. Johns’ University (Minn.).
"In addition to offering a broad range of quality and regulatory experience from over 20 years in the medical device industry, Paul has been a pioneer in the field of transcatheter mitral valve therapies, having gained CE Mark approval for one of only two transcatheter mitral repair technologies currently on the market in Europe," said Brent Ratz, Co-Founder, President, and COO of CardiAQ. "As we finalize our second-generation system and prepare to start a definitive clinical trial, I cannot think of anyone more qualified to pave the way for the European approval of the first transcatheter mitral valve implant."
Privately held CardiAQ, headquartered in Irvine, Calif., has developed a proprietary system for Transcatheter mitral valve Implantation (TMVI). Through the combination of a unique anchoring mechanism and novel delivery systems, physicians will be able to accurately and securely implant a new mitral valve within a beating heart, thus avoiding open-heart surgery. The TMVI trans-femoral procedure is designed to be performed in a cardiac catheterization laboratory similar to angioplasty or stenting, while its transapical system is designed to be used in a hybrid operating room setting. Both approaches offer the possibility of less trauma to the patient and substantial cost-savings to the healthcare system.
Source: CardiAQ Valve Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.